CNTB Stock Forecast: Connect Biopharma Holdings Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.59
−5.95% on the day

The median 12-month analyst price target for Connect Biopharma Holdings Ltd. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 45 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$40.5M
Ticker Nerd rank
45/ 100
Median analyst target
$5.00
Analysts covering
7
Revenue$2.8M+5666.7% y/y
Operating income−$17.6M
Net income−$17.3M
Free cash flow−$15.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.7%
1M
−32.5%
YTD
−79.0%
1Y
−81.2%
From 52W high
−84.0%
From 52W low
+2.0%
$0.58
$3.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Connect Biopharma Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
45/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
85
Volatility
72
Revisions
69
Momentum
44
Issuance
40
Value
33
Growth
21
Quality
7

Accruals (85): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (7): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CNTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26CNTBHigh $9.00Median $5.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7
Buy
0
Hold
0
Sell
$4.00
Low
$5.00
Median
$9.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
17 Nov 2026Canaccord GenuityMaintainsBuy$6.00
17 Nov 2026Piper SandlerMaintainsOverweight$7.00 → $5.00
28 Oct 2026HC Wainwright & Co.ReiteratesBuy$7.00
12 Oct 2026Leerink PartnersAssumesOutperform$4.00
8 Oct 2026HC Wainwright & Co.ReiteratesBuy$7.00
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$7.00
30 Sept 2026BTIGMaintainsBuy$10 → $5.00
22 Sept 2026OppenheimerMaintainsOutperform$8.00 → $5.00
17 Sept 2026HC Wainwright & Co.ReiteratesBuy$7.00
16 Sept 2026Canaccord GenuityMaintainsBuy$7.00 → $6.00
15 Sept 2026BTIGReiteratesBuy$10
9 July 2026OppenheimerInitiatesOutperform$8.00
26 June 2026Piper SandlerInitiatesOverweight—
25 June 2026HC Wainwright & Co.ReiteratesBuy—
26 May 2026Canaccord GenuityInitiatesBuy—
21 May 2026Cantor FitzgeraldInitiatesOverweight—
1 Apr 2026BTIGReiteratesBuy—
31 Mar 2026BTIGReiteratesBuy—
1 Dec 2025Lake StreetInitiatesBuy—
13 Nov 2025BTIGReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CNTB.

Market Radar

This page is one stock. Monday covers all of them.

CNTB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CNTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Connect Biopharma Holdings Ltd. returned −81.2% against +6.9% for the S&P 500, dividends included.

CNTB vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26CNTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
10.4×

Cheaper than 12% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−201.5%

Higher than 7% of US stocks

Return on assets
−90.7%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Connect Biopharma Holdings Ltd. has a market value of $40.5M and an enterprise value of $21.5M.

  • Revenue in the twelve months to 30 June 2026: $3.0M. The latest quarter grew 5666.7% year on year.

  • Net income over the same four quarters: −$69.0M, a −2336.3% net margin.

  • Diluted earnings per share, trailing twelve months: −$1.19.

  • Free cash flow in the twelve months to 30 June 2026: −$60.6M.

  • Shares outstanding: 63.0M.

  • Connect Biopharma Holdings Ltd. employs 64 people — $46K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CNTB and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTBConnect Biopharma Holdings Ltd.$40.5M45
PLRXPliant Therapeutics, Inc.$36.8M68
GRCEGrace Therapeutics, Inc.$36.0M44
TILInstil Bio, Inc.$35.5M48
DWTXDogwood Therapeutics, Inc.$39.6M71
CUECue Biopharma, Inc.$34.7M20
INKTMiNK Therapeutics, Inc.$39.8M62

Take a look at CNTB’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Connect Biopharma Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CNTB

What is the CNTB stock price forecast for 2026-2027?

The median 12-month analyst price target for Connect Biopharma Holdings Ltd. is $5, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTB stock a buy right now?

Of the 7 analysts covering Connect Biopharma Holdings Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Connect Biopharma Holdings Ltd. 45 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTB?

As at 21 Nov 2026, Connect Biopharma Holdings Ltd. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (85 of 100).

Will CNTB stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts is $5, and Ticker Nerd's factor model ranks Connect Biopharma Holdings Ltd. 45 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTB stock forecast for 2030?

No analyst covering Connect Biopharma Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has CNTB stock performed over the past year?

Connect Biopharma Holdings Ltd. returned -81.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Connect Biopharma Holdings Ltd. do?

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease.

Company

About Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.

CEO Dr. Barry David Quart Pharm.D. · 64 employees · United States · https://www.connectbiopharm.com